802 companies

Regeneron Pharmaceuticals

Market Cap: US$51.8b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

REGN

US$490.28

7D

-16.7%

1Y

-50.0%

Daiichi Sankyo Company

Market Cap: JP¥7.2t

Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally.

4568

JP¥3,842.00

7D

2.1%

1Y

-31.1%

Summit Therapeutics

Market Cap: US$13.5b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

SMMT

US$18.22

7D

-29.5%

1Y

109.7%

ALTEOGEN

Market Cap: ₩17.6t

A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

A196170

₩330,000.00

7D

2.2%

1Y

77.5%

BioMarin Pharmaceutical

Market Cap: US$11.1b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

BMRN

US$58.07

7D

0.9%

1Y

-22.6%

Moderna

Market Cap: US$10.3b

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

MRNA

US$26.56

7D

1.1%

1Y

-81.4%

Corcept Therapeutics

Market Cap: US$8.2b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

CORT

US$77.56

7D

-1.4%

1Y

157.1%

Roivant Sciences

Market Cap: US$7.5b

A clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of medicines and technologies.

ROIV

US$10.99

7D

1.1%

1Y

6.1%

Revolution Medicines

Market Cap: US$7.3b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

RVMD

US$39.40

7D

-0.9%

1Y

2.8%

Grifols

Market Cap: €5.9b

Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.

GRF

€9.47

7D

1.8%

1Y

1.5%

Jazz Pharmaceuticals

Market Cap: US$6.7b

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

JAZZ

US$108.07

7D

0%

1Y

2.7%

Repligen

Market Cap: US$6.6b

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

RGEN

US$118.07

7D

-0.07%

1Y

-20.8%

BridgeBio Pharma

Market Cap: US$6.5b

A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

BBIO

US$34.25

7D

2.7%

1Y

22.3%

Chongqing Zhifei Biological Products

Market Cap: CN¥45.8b

Chongqing Zhifei Biological Products Co., Ltd.

300122

CN¥19.14

7D

-0.9%

1Y

-41.6%

Madrigal Pharmaceuticals

Market Cap: US$6.1b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

MDGL

US$275.26

7D

2.9%

1Y

16.6%

Bruker

Market Cap: US$5.6b

Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.

BRKR

US$36.70

7D

3.4%

1Y

-44.0%

Legend Biotech

Market Cap: US$5.3b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

LEGN

US$28.95

7D

0.1%

1Y

-27.6%

Ionis Pharmaceuticals

Market Cap: US$5.3b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

IONS

US$33.51

7D

1.6%

1Y

-10.8%

Axsome Therapeutics

Market Cap: US$5.2b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

AXSM

US$105.16

7D

0.09%

1Y

43.2%

Zealand Pharma

Market Cap: DKK 32.1b

A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.

ZEAL

DKK 453.50

7D

10.9%

1Y

-29.1%

Vaxcyte

Market Cap: US$4.2b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

PCVX

US$32.49

7D

-0.2%

1Y

-53.8%

Akero Therapeutics

Market Cap: US$4.0b

Engages in the development of treatments for patients with serious metabolic diseases in the United States.

AKRO

US$49.65

7D

7.1%

1Y

163.8%

Merus

Market Cap: US$3.9b

A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.

MRUS

US$56.07

7D

1.7%

1Y

5.3%

Avidity Biosciences

Market Cap: US$3.7b

A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).

RNA

US$30.98

7D

1.3%

1Y

15.3%

Cytokinetics

Market Cap: US$3.7b

A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.

CYTK

US$31.02

7D

1.6%

1Y

-36.1%

Soleno Therapeutics

Market Cap: US$3.7b

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

SLNO

US$73.35

7D

-4.6%

1Y

74.3%

Sarepta Therapeutics

Market Cap: US$3.7b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

SRPT

US$37.60

7D

-0.8%

1Y

-71.0%

Krystal Biotech

Market Cap: US$3.6b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

KRYS

US$125.96

7D

0.7%

1Y

-21.3%

Genscript Biotech

Market Cap: HK$27.9b

An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.

1548

HK$12.82

7D

4.2%

1Y

28.2%

Alvotech

Market Cap: US$3.5b

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

ALVO

US$11.44

7D

11.3%

1Y

-17.6%

Arcellx

Market Cap: US$3.4b

Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.

ACLX

US$62.06

7D

-2.9%

1Y

19.3%

Zai Lab

Market Cap: US$3.3b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

ZLAB

US$30.14

7D

-3.8%

1Y

69.5%

Ultragenyx Pharmaceutical

Market Cap: US$3.2b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

RARE

US$34.03

7D

-4.6%

1Y

-15.2%

CRISPR Therapeutics

Market Cap: US$3.1b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

CRSP

US$36.29

7D

-1.5%

1Y

-32.5%

Viking Therapeutics

Market Cap: US$3.0b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

VKTX

US$26.80

7D

-0.7%

1Y

-57.0%

Crinetics Pharmaceuticals

Market Cap: US$2.9b

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

CRNX

US$30.51

7D

2.5%

1Y

-31.3%

Page 1 of 23